ResMed Announces Leadership Change
2022年5月6日 - 05:05AM
ResMed Announces Leadership Change
ResMed (NYSE: RMD, ASX: RMD) today announced that Jim Hollingshead,
President, Sleep and Respiratory Care, has informed ResMed that he
has accepted a new position and is leaving the company, effective
immediately. Rob Douglas, President and Chief Operating Officer,
has been appointed interim President, Sleep and Respiratory
Care.
“I’d like to thank Jim for his 12 years of service
and valuable contributions to ResMed,” said Mick Farrell, ResMed
CEO. “Jim has played an important role in our business, first as
head of our strategy and business development team, then as
president of our Americas region, and most recently as president of
our Sleep and Respiratory Care business. Jim formed part of the
global business team that created the strategy to embed
communications in our devices, supporting our transformation into a
world-leading digital health company. Together with our CEO
operations team, Jim has helped curate a team of strong leaders,
leaving ResMed well positioned for ongoing growth, as we accelerate
our business into 2025, and beyond. I wish Jim well in his new role
as a ResMed alum, and I thank Rob for stepping in on an interim
basis, as together we build upon our strong leadership
bench-strength here at ResMed.”
About ResMedAt ResMed (NYSE: RMD,
ASX: RMD) we pioneer innovative solutions that treat and keep
people out of the hospital, empowering them to live healthier,
higher-quality lives. Our digital health technologies and
cloud-connected medical devices transform care for people with
sleep apnea, COPD, and other chronic diseases. Our comprehensive
out-of-hospital software platforms support the professionals and
caregivers who help people stay healthy in the home or care setting
of their choice. By enabling better care, we improve quality of
life, reduce the impact of chronic disease, and lower costs for
consumers and healthcare systems in more than 140 countries. To
learn more, visit ResMed.com and follow @ResMed.
For
mediaJayme Rubenstein+1 858-836-6798news@resmed.com |
For
investorsAmy Wakeham+1
858.836.5000investorrelations@resmed.com |
Resmed (LSE:0KW4)
過去 株価チャート
から 2 2024 まで 3 2024
Resmed (LSE:0KW4)
過去 株価チャート
から 3 2023 まで 3 2024